IL311784A - Substituted sulfonylurea compounds as inhibitors of interleukin-1 activity - Google Patents
Substituted sulfonylurea compounds as inhibitors of interleukin-1 activityInfo
- Publication number
- IL311784A IL311784A IL311784A IL31178424A IL311784A IL 311784 A IL311784 A IL 311784A IL 311784 A IL311784 A IL 311784A IL 31178424 A IL31178424 A IL 31178424A IL 311784 A IL311784 A IL 311784A
- Authority
- IL
- Israel
- Prior art keywords
- inlerleukin
- sulfonylureas
- inhibitors
- activity
- converted
- Prior art date
Links
- 229940100389 Sulfonylurea Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021121548 | 2021-09-29 | ||
| PCT/US2022/077120 WO2023056264A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311784A true IL311784A (en) | 2024-05-01 |
Family
ID=84329267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311784A IL311784A (en) | 2021-09-29 | 2022-09-27 | Substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400561A1 (https=) |
| EP (1) | EP4408843A1 (https=) |
| JP (1) | JP2024538602A (https=) |
| KR (1) | KR20240089127A (https=) |
| CN (1) | CN118251393A (https=) |
| AU (1) | AU2022356377A1 (https=) |
| CA (1) | CA3233673A1 (https=) |
| IL (1) | IL311784A (https=) |
| MX (1) | MX2024003948A (https=) |
| WO (1) | WO2023056264A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11542255B2 (en) * | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| KR20200087759A (ko) * | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
-
2022
- 2022-09-27 JP JP2024519269A patent/JP2024538602A/ja active Pending
- 2022-09-27 KR KR1020247014041A patent/KR20240089127A/ko active Pending
- 2022-09-27 WO PCT/US2022/077120 patent/WO2023056264A1/en not_active Ceased
- 2022-09-27 MX MX2024003948A patent/MX2024003948A/es unknown
- 2022-09-27 CN CN202280075492.3A patent/CN118251393A/zh active Pending
- 2022-09-27 AU AU2022356377A patent/AU2022356377A1/en active Pending
- 2022-09-27 IL IL311784A patent/IL311784A/en unknown
- 2022-09-27 CA CA3233673A patent/CA3233673A1/en active Pending
- 2022-09-27 EP EP22801649.9A patent/EP4408843A1/en active Pending
- 2022-09-27 US US18/696,901 patent/US20240400561A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022356377A1 (en) | 2024-04-11 |
| WO2023056264A1 (en) | 2023-04-06 |
| CN118251393A (zh) | 2024-06-25 |
| EP4408843A1 (en) | 2024-08-07 |
| JP2024538602A (ja) | 2024-10-23 |
| US20240400561A1 (en) | 2024-12-05 |
| KR20240089127A (ko) | 2024-06-20 |
| MX2024003948A (es) | 2024-06-28 |
| CA3233673A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280139A (en) | Sulphonylureas as inhibitors of interleukin-1 activity | |
| EP4173353C0 (en) | CONFIGURATION OF LOW ENERGY POSITIONING MEASUREMENTS | |
| AR120184A1 (es) | Aminas bicíclicas como inhibidoras de la cdk2 | |
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| EP4126179A4 (en) | MOLDED SWAB HEAD | |
| MA55695A (fr) | Composés chimiques comme inhibiteurs de l'activité interleukine-1 | |
| ATE552255T1 (de) | 4-aminoindazole | |
| EP4508919C0 (en) | CONFIGURATION OF MULTIPLE TIME ADVANCE VALUES | |
| EP4238974A4 (en) | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND | |
| EP4333821A4 (en) | SARS-COV-2 INHIBITORS | |
| ECSP21090462A (es) | Aril amidinas fungicidas | |
| EP4240363A4 (en) | 2-AMINOQUINAZOLINE 7-PHENYL SUBSTITUTED, HPK1 INHIBITORS | |
| IL281742A (en) | Novel compounds as nadph oxidase inhibitors | |
| IL313475A (en) | Use of isoxazolinecarboxamide for sprout inhibition | |
| EP4360641A4 (en) | USE OF MAZDUTIDE | |
| EP4305043A4 (en) | Purification of sialooligosaccharides | |
| IL311784A (en) | Substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| UY37121A (es) | Compuestos de N-(2-(fenil) piridina-4-il)-5-morfolinopiridina-3-sulfonamida como inhibidores de la actividad PL3-quinasa | |
| IL310871A (en) | Thiadiazolone derivatives useful as ampk activator | |
| EP4349335A4 (en) | USE OF 5-NITRO-8-HYDROXYQUINOLINE | |
| IL285119A (en) | Use of spiropidion | |
| DK3790529T3 (da) | Formulering omfattende aktivt oxygen | |
| IL315118A (en) | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin- 1 activity | |
| EP4271679A4 (en) | AMORPHOUS FORM OF PRETOMANIDES | |
| EP4404792C0 (de) | Möbelstück |